A Phase 3, Multicenter, Open Label, Randomized Study Of Abarelix Versus Leuprolide Plus Daily Antiandrogen In Men With Prostate Cancer

Trachtenberg, John; Gittleman, Marc; Steidle, Christopher P.; Barzell, Winston; Friedel, William; Pessis, Dennis; Fotheringham, Nick; Campion, Marilyn; Garnick, Marc B.

doi:10.1097/00005392-200204000-00021

Cited by 129 publications

(66 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Praecis is also seeking to market abarelix in Europe. In 170 men with prostate cancer, testosterone rapidly declined after the first injection of abarelix on day one, reaching castrate levels (< 5 nmol/L) in 95% of patients on day 29, which is comparable to 7.5 mg of Lupron Depot [28]. Fluctuating testosterone levels were not reported in this paper.…”

Section: Gnrh I Receptor Gnrh Ii Receptormentioning

confidence: 43%

Gonadotropin-releasing hormone antagonists

Herbst¹

2003

Current Opinion in Pharmacology

View full text Add to dashboard Cite

Section: Gnrh I Receptor Gnrh Ii Receptormentioning

confidence: 43%

Gonadotropin-releasing hormone antagonists

Herbst¹

2003

Current Opinion in Pharmacology

View full text Add to dashboard Cite

“…Şu anda klinik kullanımları, sadece aylık formulasyonlarının bulunması, sınırlı klinik çalışmaları-nın olması, uzun dönem sonuçlarının bilinmemesi, hastaların yaklaşık %5'inde histamin aracılı ciddi ve hayatı tehtit edecek derecelere ulaşabilen yan etkilerinin bulunması nedeniyle sınırlıdır. [24] Lokal ileri ve metastatik 610 prostat kanseri hastası ile yapılan randomize faz III bir çalışmada, Degarelix'in, leuprolid asetat ile benzer etkinlikte olduğu, fakat daha hızlı ve flair fenomeni olmaksızın testosteron düşüşü sağladığı görülmüştür. [25] Antiandrojenler Prostat hücre nükleusundaki reseptörlerin bağ-lanma alanlarında testosteron ve DHT ile yarışırlar.…”

Section: Medikal Kastrasyonunclassified

Hormonal therapy in advenced stage prostate cancer

Hacıbekiroğlu¹

2015

TJ Oncol

View full text Add to dashboard Cite

Prostat cancer is the most common type of cancer in men. At the time of diagnosis, only 5% of prostat cancer patients have the disease in advanced stage. While the 5 year overall survival rate of the patients with locoregional disease is close to 100%, this ratio in patients with advanced disease decreases to 28%. Prostat cancer cells depend on androgens for development, proliferation and physiological function. The purpose of the standard hormone therapy is to keep testesteron levels in castrate levels. Androgen deprivation therapy (ADT) is the standard treatment approach in prostat cancer patients with advanced stage. Although this treatment possesses many clinical benefits, it has also side effects affecting many systems in the body. This article evaluated the types and mechanisms of action of ADT, the management of this treatment's side effects, and the controversial situations commonly encountered in daily oncology practice in the light of current literature.Key words: Androgen deprivation therapy; prostate cancer.Prostat kanseri, erkeklerde en yaygın kanser türüdür. Prostat kanseri, tanı anında hastaların sadece %5'i ileri evre hastalığa sahiptir. Ancak hastalarda, 5 yıllık sağkalım, lokorejyonel hastalıkta %100'lerde iken, ileri evre hastalıkta bu oran %28'lere inmektedir. Prostat kanser hücreleri gelişme, proliferasyon ve fonksiyonları için androjenlere fizyolojik bağımlıdır. Standart hormon tedavisinin amacı ise testosteron düzeyini kastrasyon seviyelerinde tutmaktır. Androjen deprivasyon tedavisi (ADT), ileri evre prostat kanserinde standart tedavi yaklaşımıdır. ADT, klinik faydalarına ek olarak, vücuttaki birçok sistemi etkileyen yan etkilere sahiptir. Bu yazıda, ADT çeşitleri ve etkinlik mekanizmaları, günlük onkoloji pratiğinde sık karşılaşılan tartışmalı durumlar ve yan etki yönetimi güncel literatür bilgileri eşliğinde değer-lendirildi.

show abstract

“…In a 3-month US trial, 269 men with locally advanced and metastatic disease were randomized to abarelix 100 mg (n ¼ 180) or leuprolide 7.5 mg (n ¼ 89) monthly; the abarelix group received an additional injection on day 15 [McLeod et al 2001]. In the second US trial, 255 patients with stage D1/D2 disease were randomized to abarelix 100 mg monthly (n ¼ 170) or leuprolide 7.5 mg monthly and bicalutamide 50 mg daily (n ¼ 85) over 24 weeks [Trachtenberg et al 2002]. In the European phase III trial, 177 patients with advanced or metastatic cancer were treated for 48 weeks with abarelix 100 mg 4-weekly or goserelin 3.6 mg 4-weekly plus bicalutamide 50 mg daily [Selvaggi et al 2001].…”

Section: Clinical Efficacymentioning

confidence: 99%

An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer

Boccon-Gibod

Meulen

Persson

2011

Therapeutic Advances in Urology

View full text Add to dashboard Cite

Androgen deprivation therapy (ADT) is the main treatment approach in advanced prostate cancer and in recent years has primarily involved the use of gonadotropin-releasing hormone (GnRH) agonists. However, despite their efficacy, GnRH agonists have several drawbacks associated with their mode of action. These include an initial testosterone surge and testosterone microsurges on repeat administration. GnRH antagonists provide an alternative approach to ADT with a more direct mode of action that involves immediate blockade of GnRH receptors. Antagonists produce a more rapid suppression of testosterone (and prostatespecific antigen [PSA]) without a testosterone surge or microsurges and appear to offer an effective and well tolerated option for the hormonal treatment of prostate cancer. Comparisons with GnRH agonists have shown GnRH antagonists to be at least as effective in achieving and maintaining castrate testosterone levels in patients with prostate cancer. Furthermore, with antagonists, the lack of an initial testosterone surge (which may cause clinical flare) may allow more rapid relief of symptoms related to prostate cancer, avoid the need for concomitant antiandrogens to prevent clinical flare (so avoiding any antiandrogen-associated adverse events) and allow GnRH antagonist use in patients with high tumour burden and/or acute problems such as spinal cord compression. Although several antagonists have been investigated, only degarelix and abarelix are currently available for clinical use in prostate cancer. Currently, degarelix is the most extensively studied and widely available agent in this class. Degarelix is one of a newer generation of antagonists which, in a comprehensive and ongoing clinical development programme, has been shown to provide rapid, profound and sustained testosterone suppression without the systemic allergic reactions associated with earlier antagonists. This review examines the currently available data on GnRH antagonists in prostate cancer.

show abstract

A Phase 3, Multicenter, Open Label, Randomized Study Of Abarelix Versus Leuprolide Plus Daily Antiandrogen In Men With Prostate Cancer

Cited by 129 publications

References 10 publications

Gonadotropin-releasing hormone antagonists

Gonadotropin-releasing hormone antagonists

Hormonal therapy in advenced stage prostate cancer

An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer

Contact Info

Product

Resources

About